Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel,
Acta Haematol. 2020;143(4):343-351. doi: 10.1159/000506919. Epub 2020 May 14.
Cardiac amyloidosis, the majority of cases of which are due to immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), affects different aspects of the heart and cardiovascular system. Amyloid-induced cardiomyopathy, clinically manifesting with heart failure and electrophysiological abnormalities, has distinct characteristics compared to non-amyloid cardiomyopathies. Accordingly, specific management strategies are required. This paper will review the cardiovascular manifestations of patients with cardiac amyloidosis and their suggested treatment strategies, emphasizing the importance of multidisciplinary care.
心脏淀粉样变,大多数病例是由于免疫球蛋白轻链淀粉样变(AL)和转甲状腺素蛋白淀粉样变(ATTR)引起的,影响心脏和心血管系统的不同方面。淀粉样物质诱导的心肌病,临床上表现为心力衰竭和电生理异常,与非淀粉样心肌病有明显不同。因此,需要采用特定的管理策略。本文将回顾心脏淀粉样变患者的心血管表现及其建议的治疗策略,强调多学科护理的重要性。